PMID- 2472878
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20161123
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 49
IP  - 15
DP  - 1989 Aug 1
TI  - Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma 
      using polylactic acid microspheres containing aclarubicin hydrochloride.
PG  - 4357-62
AB  - Transcatheter arterial chemoembolization therapy using polylactic acid 
      microspheres containing aclarubicin hydrochloride (ACR) was performed in 62 
      patients with primary hepatocellular carcinoma. These microspheres were about 200 
      microns in diameter and contained 10% (w/w) aclarubicin. A single dose of 
      polylactic acid microspheres containing ACR (50-100 mg of ACR) was administered 1 
      to 8 times with a mean of 2.2 doses (a total of 160 treatments) in 62 patients. 
      Antitumor effects were observed from the decrease in serum alpha-fetoprotein 
      levels (82.1% of the patients) and in two dimensional size of tumor on computed 
      tomography (93.6%). The cumulative survival rate was 54.3% at 1 year, 24.6% at 2 
      years, and 19.2% at 3 years, respectively, among 59 patients with unresectable 
      tumors. In 3 resected liver specimens, there was a significant accumulation of 
      ACR in the tumor, and severe necroses of the tumors were observed histologically. 
      Systemic toxicity was mild and all patients tolerated this treatment. These 
      results suggest that transcatheter arterial chemoembolization with the use of 
      polylactic acid microspheres containing ACR is a useful tumor-targeting 
      chemotherapy and is effective in the treatment of hepatocellular carcinoma.
FAU - Ichihara, T
AU  - Ichihara T
AD  - Department of Surgery II, Kumamoto University Medical School, Japan.
FAU - Sakamoto, K
AU  - Sakamoto K
FAU - Mori, K
AU  - Mori K
FAU - Akagi, M
AU  - Akagi M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Lactates)
RN  - 0 (Polyesters)
RN  - 0 (Polymers)
RN  - 0 (alpha-Fetoproteins)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 459TN2L5F5 (poly(lactide))
RN  - 74KXF8I502 (Aclarubicin)
SB  - IM
MH  - Aclarubicin/*administration & dosage/therapeutic use
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Carcinoma, Hepatocellular/*drug therapy/mortality/pathology
MH  - Dogs
MH  - Embolization, Therapeutic
MH  - Female
MH  - Humans
MH  - Infusions, Intra-Arterial
MH  - Lactates/*administration & dosage
MH  - *Lactic Acid
MH  - Liver Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Microspheres
MH  - Middle Aged
MH  - Polyesters
MH  - Polymers/*administration & dosage
MH  - alpha-Fetoproteins/analysis
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1989 Aug 1;49(15):4357-62.